154
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Abnormal uterine bleeding as a presenting symptom is related to multiple uterine leiomyoma: an ultrasound-based study

, , &
Pages 689-694 | Published online: 18 Oct 2013

Abstract

Purpose

To determine the prevalence of uterine leiomyomas, diagnosed by ultrasound, in a private health care setting located in the central eastern region of Portugal, and to explore the demographic and clinical factors related to diagnosis and symptomatology.

Patients and methods

The files of 624 patients attending a private clinic in Covilhã, Portugal, from January 2 to December 31, 2010 were retrieved for evaluation. Pelvic ultrasound record, age, weight, height, age at menarche, number of pregnancies and deliveries, marital status, menstrual cycles characteristic, and contraceptive method at consultation were included in the analysis.

Results

Uterine leiomyoma (UL) was diagnosed by ultrasonography in 161 (25.8%) patients. A single UL was diagnosed in 80 (49.7%) patients. In 79 (49.1%) patients, the largest leiomyoma had a dimension <20 mm. Prevalence of UL was age dependent: at 11.0% for women 20–39 years old; 45.4% for those aged 40–59 years; and 19.5% for women 60 years or older. Metrorrhagia was the most distressing presenting symptom. When menorrhagia was the presenting symptom, the probability of having an ultrasound diagnosis of UL was 73.3%. Metrorrhagia or menorrhagia, as presenting symptom, was significantly related to the ultrasound diagnosis of multiple ULs.

Conclusion

UL was especially prevalent in women aged between 40 and 59 years. Patients with multiple ULs had significantly more abnormal uterine bleeding. In patients with menorrhagia or metrorrhagia, special attention should be taken in searching for the presence of multiple ULs during ultrasound.

Introduction

Leiomyomas, also known as fibroids, are the most frequent benign uterine tumors to develop during a woman’s reproductive years; occurrence tends to regress after menopause.Citation1 Malign transformation of uterine leiomyoma (UL) seems to be a very rare event,Citation2 but they are symptomatic in 20%–30% of cases and are the main reason for approximately one-third of all hysterectomies in developed countries.Citation3,Citation4 Symptoms related to UL are menstrual disorders, mainly menorrhagia, pelvic pain, and infertility, which can adversely affect pregnancy outcomes.Citation5,Citation6 UL disproportionately affects Black women.Citation4,Citation7,Citation8 The etiology of UL is unknown, but it can be influenced by genetic liability,Citation9 hormonal environment,Citation10,Citation11 and local tissue mediators.Citation10,Citation12 Definitive prevalence of UL in the general female population is also unknown, but differs by ethnicity, age, and method used for diagnosis.Citation13 In clinical practice, transvaginal ultrasonography (TVS) is the most widespread method for evaluating UL, with an estimated accuracy of 87%–92%.Citation14Citation16

The objective of this study was to determine the prevalence of UL, diagnosed by TVS, at a private health care setting located in the central eastern part of Portugal, and to explore the demographic and clinical factors related to diagnosis and symptomatology.

Materials and methods

The study retrospectively analyzed the medical files of all female patients who consecutively attended a gynecological consultation at a private health care setting located in Covilhã, Portugal, from December 2–31, 2010. Excluded from the study were virgins, patients who had previously undergone a hysterectomy, or those pregnant at the time of the consultation. All included patients were Caucasian, except three, who were African.

The same gynecologist (JAF), who has more than 20 years of gynecological experience and competence in the practice of gynecologic ultrasound, attended all patients.

Policies of the private clinic include recording of demographic and clinical data from every patient in a standard digital database. In all cases, an office TVS was offered to the patient. The sonographic equipment used was a Nemio 17 (SSA-550A) with a PVM-651VT 6 MHz endovaginal probe (Toshiba Corporation, Tokyo, Japan).

For the anonymous use of data from patient files, written consent was obtained from the clinical director of the private health care clinic. LSB and DGT analyzed the files of 624 patients who met the inclusion criteria, and from each file they retrieved age, weight, height, age at menarche, number of pregnancies and deliveries, marital status, menstrual cycles characteristics, and contraceptive method at time of consultation. The presence, number, and largest dimension of the ULs were retrieved from TVS records. For analysis, the data recorded at the first consultation in 2010 were considered. Ultrasound records were analyzed for the presence or absence of UL, their number, location and largest dimension.

The data were organized and analyzed in Statistical Package for the Social Sciences® software ([SPSS] v 20.0 for Windows; IBM Corporation, Armonk, NY, USA), by SMN. Univariate analysis and multivariate logistic regression analysis were performed. In all cases, P < 0.05 was considered significant.

Results

Using TVS, UL was diagnosed in 161 (25.8%) of those 624 cases included in the study. From those 161 patients with an ultrasound-based diagnosis of UL, 99 (61.5%) had previous knowledge of the disease. In three patients, resectoscopic myomectomy was proposed for treating symptomatic sub-mucous leiomyoma.

The demographic characteristics of the studied population are shown in . The mean age was 39.6 years; 66.2% of the women were married; 68.2% reported having had at least one pregnancy and 64.2% at least one delivery; 31.6% were asymptomatic. UL was diagnosed by ultrasound in 11.0% of all women aged 20 to 39 years old, in 45.4% of all women aged 40 to 59 years, and in 19.5% of all women aged 60 years or more. Metrorrhagia and menorrhagia were the most usual presenting symptoms, and were recorded in 11.3% of all cases and in 22.3% of all women with an ultrasound diagnosis of UL.

Table 1 Demographic characteristics (624 cases)

The uterus was explored with clinical bimanual palpation and TVS. Results of clinical and ultrasound exploration of the uterus are shown in . The overall prevalence of UL was 17.0% by bimanual palpation and 25.8% by TVS. ULs larger than 3.0 cm were identified through ultrasound imaging in 24.2% of the cases.

Table 2 Clinical and ultrasound uterus exploration data (624 cases)

In order to uncover significant demographic and clinical differences between women with and without ultrasound diagnosis of UL, a univariate analysis was performed (). Significant factors associated with an ultrasound-based diagnosis of UL were the following: 40 to 59 years of age; married; excessive body weight (obese); prior pregnancy or delivery; non-use of the combined pill for contraception; and symptoms of menorrhagia. However, after adjustment by multivariate logistic regression analysis, age 40 to 59 years remained the single demographic and clinical factor found to be statistically associated with ultrasonographic diagnosis of UL.

Table 3 Univariate analysis of demographic and clinical characteristics between patients with and without sonographic diagnosis of uterine leiomyoma

Menorrhagia, metrorrhagia, and pelvic pain were the most frequent presenting symptoms. When menorrhagia was the presenting symptom, an ultrasound imaging diagnosis of UL was made in 73.3% of cases (). Plotting a univariate analysis, metrorrhagia and menorrhagia as presenting symptoms were significantly related to the TVS diagnosis of multiple ULs, but not with the largest UL dimension ( and ). Although lacking statistical significance, patients diagnosed with smaller ULs seemed to be more symptomatic ().

Table 4 Presenting symptoms according to number of uterine leiomyomas at ultrasound

Table 5 Presenting symptoms according to size of largest uterine leiomyoma at ultrasound

Discussion

The real prevalence of UL in the general population is unknown. UL prevalence has been evaluated by different methods, such as population surveys,Citation17 pathologic study of surgical specimens of hysterectomy,Citation18 postmortem of women who died without gynecological diseases,Citation19 and pelvic ultrasonography,Citation13,Citation20,Citation21 with, as expected, different results.

Kratochwil et alCitation22 introduced ultrasound imaging of feminine pelvic organs in 1972. In 1980, Muram et alCitation23 defined criteria for UL identification with TVS as a relatively spherical mass that is echogenically different from the surrounding myometrium. Since then, TVS has become the most noninvasive, lowest-cost, and widespread method for evaluation of uterine pathology, with highly accurate performance.Citation14Citation16 The main disadvantage of ultrasound is that it is an operator-and device-dependent technique.Citation24 In order to improve UL diagnosis accuracy, saline contrast sonohysterography and three-dimensional ultrasound have been proposed, although with conflicting results.Citation24,Citation25 Nowadays, two-dimensional pelvic ultrasonography remains the best method for routine detection of ULs.Citation24,Citation25 Ultrasonography has been shown to be an insufficient method of myoma mapping, and magnetic resonance imaging should preferred for surgical therapy planning.Citation25

In the present study, we found a 25.8% overall prevalence of UL, with the highest prevalence (45.4%) in women aged 39–50 years, which is in accordance with previous ultrasound-based studies.Citation13,Citation20,Citation26 Multiple ULs were present in 50.1% of cases, which is lower than that reported in surgical specimens by Cramer and Patel (84%).Citation18 In contrast to Cramer and Patel’s findings, only 49.1% patients had a UL larger than 20 mm. A previous diagnosis of UL had been made in 99 (61.5%) patients, who were in watchful waiting management, which has been considered as a safe management option for asymptomatic UL.Citation27,Citation28 Except in three cases submitted to resectoscopy for treatment of symptomatic submucous myomas, the main component of the leiomyomas was intramural. A purely intramural myoma represents a temporary status, and its growth is dependent on the existing hormonal conditions of the woman.Citation29

Most of the knowledge about demographic and clinical risk factors for UL is based on results of large populations survey studies. Risk factors such as age, ethnicity, education, hormonal factors, diet, physical exercise, oral contraceptives use, childbirth, smoking and tissue injury has been reported, with conflicting results. In accordance with other ultrasound-based studies,Citation13,Citation20,Citation26 after multivariate statistical analysis, we don’t found any demographic or clinical risk factor for UL, with exception of age.

The most common symptom of UL is abnormal uterine bleeding, especially menorrhagia.Citation5 The mechanism of leiomyoma-associated menorrhagia is unknown, but submucous localization, vascular defects, and impaired endometrial hemostasis have been suggested as possible explanations.Citation30,Citation31 Even small ULs without distortion of the endometrial cavity can alter myometrial vascularization and contractibility. A meta-analysis conducted by Benecke et alCitation32 reported that intramural ULs may have a negative impact on fertility. In our series, menorrhagia was significantly associated with multiplicity of ULs, but not with the volume of the largest one, suggesting the importance of factors other than those associated with distortion of the myometrium and endometrial cavity. Extracellular matrix that embed UL cells influence both normal myometrial and UL cells, promoting proliferative activity and decreasing apoptosis.Citation33,Citation34 Previous ultrasound-based studiesCitation20Citation35 have reported that the presence, number, and volume of leiomyomas are unrelated to abnormalities in the menstrual cycle. Other studies,Citation36,Citation37 but not all,Citation38 suggest that menstrual symptoms are related to tissue layer location in the uterine wall and with the axial position of leiomyomas. In our study, multiplicity of ULs was significantly related to abnormal uterine bleeding (menorrhagia and metrorrhagia) as a presenting symptom.

Currently, most women with menstrual disorders and multiple ULs are scheduled for medical therapy followed by hysterectomy or myomectomy.Citation39 Hysterectomy seems a good option when childbearing wishes have been fulfilled;Citation39 but it is not devoid of risks, morbidity and mortality as for any surgical procedure. Myomectomy is indicated for those women who wish to retain their fertility.Citation39 The major disadvantage of surgical myomectomy is leiomyoma recurrence. In next 5 years, more than one-third of that women submitted to myomectomy will need additional surgical intervention for treatment of newly developed ULs.Citation40 Minimally invasive procedures, such as laparoscopic myolysis, uterine artery embolization, uterine fibroid embolization, and magnetic resonance-guided focused ultrasound, as standard practice for treatment of symptomatic multiple ULs are currently limited.Citation41 It seems obvious that new treatments better than surgical approaches are needed for the management of symptomatic UL.

In recent years, intense scientific research has brought new insights on UL biology. The development of ULs has been shown to be dependent of sex steroids, especially progesterone,Citation42,Citation43 and many leiomyoma-related growth factors have been identified, including epidermal growth factor, platelet-derived growth factor, transforming growth factor beta, insulin-like growth factor, activin, and myostatin. We speculate that, in patients with multiple ULs and menstrual disorders, each UL can produce different kinds of growth factors or other biological mediators that may have additive negative effects on the myometrial and endometrial environment.

Discovery of selective progesterone receptor modulators (SPRMs) has provided a new paradigm for treatment of symptomatic UL. Antiproliferative, growth factors down-regulation, and proapoptotic actions of SPRMs had been reported in vitro studies over cultured leiomyoma cells.Citation43 Randomized, placebo-controlled clinical trials have demonstrated that the SPRM ulipristal can suppress menstrual bleeding, restore normal levels of hemoglobin, reduce UL volume, and improve leiomyoma-related symptoms.Citation44,Citation45

The main objective of symptomatic UL treatment is to regress symptomatology, because expectant management is suitable for most asymptomatic leiomyomas.Citation27,Citation28 It is expected that new therapies for the treatment of UL-associated symptomatology will be developed, based on the growing knowledge of functional aspects and regulatory mechanisms of leiomyoma biology and uterine homeostasis.

Conclusion

To our knowledge, this is the first population study conducted in Portugal to assess the prevalence and demographic and clinical factors associated with the diagnosis of UL by ultrasound. In our Portuguese population, the prevalence of uterine leiomyoma increases with age, and was similar to that reported in literature for White women.

Menorrhagia and metrorrhagia were the more distressing symptoms, especially in patients with multiple ULs diagnosed by TVS. In patients with abnormal uterine bleeding, special attention should be taken to search for multiple leiomyomas during pelvic ultrasound examination.

Further studies are needed to assess the biology and symptomatic impact of multiple versus single ULs, in order to find more efficient therapeutic approaches.

Disclosure

Publication processing fees for this paper were paid by Gedeon Ritcher. The authors have no other conflicts of interest to report.

References

  • WalkerCLStewartEAUterine fibroids: the elephant in the roomScience20053081589159215947177
  • SchwartzPEKellyMGMalignant transformation of myomas: myth or reality?Obstet Gynecol Clin North Am20063318319816504815
  • ParkerWHEtiology, symptomatology, and diagnosis of uterine myomasFertil Steril20078772573617430732
  • WiseLAPalmerJRStewartEARosenbergLAge-specific incidence rates for self-reported uterine leiomyomata in the Black Women’s Health StudyObstet Gynecol200510556356815738025
  • ButtramVCJrReiterRCUterine leiomyoma: etiology, symptomatology and managementFertil Steril1981364334457026295
  • HaneyAFClinical decision making regarding leiomyomata: what we need in the next millenniumEnviron Health Perspect2000108Suppl 583583911035991
  • HuyckKLPanhuysenCICuencoKTThe impact of the race as a risk factor for symptoms severity and age at diagnosis of uterine leiomyomata among affected sistersAm J Obstet Gynecol20081982168 e118226615
  • MarshallLMSpiegelmanDBarbieriRIVariation in the incidence of uterine leiomyoma among premenopausal women by age and raceObstet Gynecol1997909679739397113
  • VikhlyaevaEMKhodzhaevaZSFantschenkoNDFamilial predisposition to uterine leiomyomasInt J Gynaecol Obstet1995511271318635633
  • AndersenJGrowth factors and cytokines in uterine leiomyomasSemin Reprod Endocrinol1996142692828885057
  • SchwartzSMMarshallLMBairdDDEpidemiologic contributions to understanding the etiology of uterine leiomyomataEnviron Health Perspect2000108582182711035989
  • CheginiNProinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorderSemin Reprod Med201028318020320414842
  • BairdDDDunsonDBHillMCCousinsDSchectmanJMHigh cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidenceAm J Obstet Gynecol200318810010712548202
  • KurtzABMiddletonWDUltrasoundSt Louis, MOMosby1996
  • SauerbrelEENguyenKTNolanRLA Practical Guide to Ultrasound in Obstetrics and Gynecology2nd edPhiladelphia, PALippincott-Raven1998
  • CallenPWUltrasonography in Obstetrics and Gynecology5th edPhiladelphia, PASaunders Elsevier2007
  • DownesESikiricaVGilabert-EstellesJThe burden of uterine fibroids in five european countriesEur J Obstet Gynecol Reprod Biol2010152195102
  • CramerSFPatelAThe frequency of uterine leiomyomasAm J Clin Pathol1990944354382220671
  • MichelettiARMacedoACSilvaGBBenign and malignant neoplasias in 261 necropsies for HIV-positive patients in the period of 1989 to 2008Rev Inst Med Trop Sao Paulo20115363019314
  • MarinoJLEskenaziBWarnerMUterine leiomyoma and menstrual cycle characteristics in a population-based cohort studyHum Reprod2004192350235515242998
  • MarshEEEkpoGECardozoERBrocksMDuneTCohenLSRacial differences in fibroids prevalence and ultrasound findings in asymptomatic young women (18–30 years old): a pilot studyFertil Steril2013991951195723498888
  • KratochwilAUrbanGFriedrichFUltrasonic tomography of the ovariesAnn Chir Gynaecol Fenn19726142112144640305
  • MuramDGilliesonMWaltersJHMyomas of the uterus in pregnancy: ultrasonographic follow-upAm J Obstet Gynecol198013816197416201
  • VitielloDMcCarthySDiagnostic imaging of myomasObstet Gynecol Clin North Am200633859516504808
  • StamatopoulosCPMikosTGrimbizisGFValue of magnetic resonance imaging in diagnosis of adenomyosis and myomas of the uterusJ Minim Invasive Gynecol201219562062622935303
  • BorgfeldtCAndolfETransvaginal ultrasonographic findings in the uterus and endometrium: low prevalence of leiomyoma in a random sample of women age 25–40 yearsActa Obstet Gynecol Scand200079320220710716301
  • CarlsonKJMillerBAFowlerFJJrThe Maine Women’s Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic painObstet Gynecol19948345665728134067
  • FarquharCArrollBEkeromaAAn evidence-based guidance for the management of uterine fibroidsAust NZ J Obstet Gynaecol200114125140
  • BettocchiSSiristatidisCPontrelliGThe destiny of myomas: should we treat small submucous myomas in women of reproductive age?Fertil Steril200890490591018163996
  • DubuissonJBChapronCFauconnierAKreikerGLaparoscopic myomectomy and myolysisCurr Opin Obstet Gynecol1997942332389263713
  • AndersenJFactors in fibroid growthBaillieres Clin Obstet Gynaecol199812222524310023420
  • BeneckeCKrugerTFSiebertTIVan der MerweJPSteynDWEffect of fibroids on fertility in patients undergoing assisted reproduction. A structured literature reviewGynecol Obstet Invest20055922523015775685
  • ZaitsevaMVollenhovenBJRogersPAIn vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cellsMol Hum Reprod20061218720716524927
  • CiarmelaPIslamMSReisFMGrowth factors and myometrium: biological effects in uterine fibroids and possible clinical implicationsHum Reprod Update201117677279021788281
  • FaersteinESzkloMRosensheinNRisk factors for uterine leiomyoma: a practical-based case control study. I. African-American heritage, reproductive history, body size, and smokingAm J Epidemiol2001153111011159139
  • Clevenger-HoeftMSyropCHStovallDWVan VoorhisBJSonohysterography in premenopausal women with and without abnormal bleedingObstet Gynecol19999451652010511351
  • AkkadAAHabibaMAIsmailNAbramsKal-AzzawiFAbnormal uterine bleeding on hormonal replacement: the importance of intrauterine structural abnormalitiesObstet Gynecol19958633303347651636
  • WegienkaGBairdDDHertz-PicciottoISelf-reported heavy bleeding associated with uterine leiomyomataObstet Gynecol2003101343143712636944
  • DuhanNCurrent and emerging treatments for uterine myoma – an updateInt J Womens Health2011323124121892334
  • StewartEAFaurAVWiseLAReillyRJHarlowBLPredictors of subsequent surgery for uterine leiomyomas after abdominal myomectomyObstet Gynecol20029942643211864669
  • SharpHTAssessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomataObstet Gynecol2006108990100317012464
  • SchweppeKWLong-term use of progestogens – effects on endometriosis, adenomyosis and myomasGynecol Endocrinol200723Suppl 1172117943535
  • MaruoTOharaNYoshidaSLessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomasExpert Opin Drug Discov2011689791122646213
  • LevensEDPotlog-NahariCArmstrongAYCDB-2914 for uterine leiomyomata treatment: a randomized controlled trialObstet Gynecol20081111129113618448745
  • NiemanLKBlockerWNanselTEfficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double blinded, placebo-controlled, phase IIb studyFertil Steril20119576777221055739